Nucleic acid probes complementary to human papilloma virus nucleic acid

• US 6,583,278 B1
• Filed: 11/14/1996
• Issued: 06/24/2003
• Est. Priority Date: 11/15/1995
• Status: Expired due to Fees

• Current Assignee: Gen-Probe Incorporated (Hologic Incorporated)
• Original Assignee: Gen-Probe Incorporated (Hologic Incorporated)
• Inventors: Carter, Nick M.
• Primary Examiner(s): FREDMAN, JEFFREY NORMAN
• Application Number:
  US08/749,955
• Time in Patent Office: 2,413 Days
• Field of Search: 435/6, 435/91.1, 435/91.2, 536/23.1, 536/24.3, 536/24.31, 536/24.32, 536/24.33
• US Class Current: 536/24.3
• CPC Class Codes: C12Q 1/6865 Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 1/708 for papilloma
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays

Abstract

The present invention describes oligonucleotides targeted to HPV Type 16 and/or Type 18 nucleic acid sequences which are particularly useful to aid in detecting HPV type 16 and or 18. The oligonucleotides can aid in detecting HPV Type 16 and/or Type 18 in different ways such as by acting as hybridization assay probes, helper probes, and/or amplification primers.

Claims

1. An oligonucleotide 10 to 100 bases in length, said oligonuleotide comprising a nucleotide base sequence which is at least 70% complementary to 10 or more contiguous nucleotide bases present in a target region consisting of a nucleotide base sequence selected from the group consisting of SEQ ID NO:

113, SEQ ID NO;

114, SEQ ID NO;

115 and SEQ ID NO;

116, wherein said oligonucleotide will hybridize to an HPV Type 16 target nucleic acid to form a target;

oligonucleotide duplex under slective stringency hybridization conditions and which will not form a non-target;

oligonucleotide duplex with nucleic acic from HPV Types 6, 11, 31, 33, 35, 39, 45, 51, 52, and/or 58 under said conditions.

2. The oligonucleotide of claim 1, wherein said oligonucleotide consists of a base sequence selected from the group consisting of SEQ ID NO:

113, SEQ ID NO;

114, SEQ ID NO;

115, and SEQ ID NO;

116.

3. The oligonucleotide of claim 1, wherein said oligonucleotide will hybridize to HPV Type 18 target nucleic acid.

4. The oligonucleotide of claim 2, wherein said oligonucleotide will hybridize to HPV Type 18 target nucleic acid.

5. A composition for amplifying an HPV Type 16 target nucleic acid and not for amplifying HPV Types 6, 11, 31, 33, 35, 39, 45, 51, 52, and/or 58 nucleic acid, said composition comprising:

a nucleic acid polymerase; and

at least one amplification oligonucleotide, 10 to 100 bases in length, optionally comprising a promoter sequence, said amplifiation oligonucleotide comprising a base sequence which is complementary to 10 or more contiguous nucleotide bases present in a target region consisting of a nucleotide base sequence selected from the group consisting of SEQ ID NO;

114, the complement of this sequence, and the RNA equivalents thereof, which, when contacted with said HPV Type 16 target nucleic acid under amplification conditions, will hybridize to said HPV Type 16 target nucleic acid.

6. The composition of claim 5, wherein said amplification oligonucleotide comprises the nucleotide base sequence selected from the group consisting of SEQ ID NO:

113, the complement of this sequence, and the RNA equivelents thereof.

7. The composition of claim 5, wherein said amplification oligonucleotide consists of the nucleotide base sequence, optionally attached to a promoter sequence, selected from the group consisting of SEQ ID NO:

113, the complement of this sequence, and the RNA equivalents thereof.

8. The composition of claim 5, wherein said amplification oligonucleotide will hybridize to HPV Type 18 target nucleic acid.

9. The composition of claim 6, wherein said amplification oligonucleotide will hybridize to HPV Type 18 target nucleic acid.

10. The composition of claim 7, wherein said amplification oligonucleotide will hybridize to HPV Type 18 target nucleic acid.